X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
QL1706 (iparomlimab and tuvonralimab) in combination with chemotherapy, with or without bevacizumab, as a first-line treatment of recurrent or metastatic cervical cancer (r/mCC).
Lead Product(s): Iparomlimab,Tuvonralimab
Therapeutic Area: Oncology Product Name: QL1706
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2023
Details:
Under the terms of the agreement, Qilu Pharmaceutical will gain the rights for the development and commercialization of AB-729 for the treatment or prevention of hepatitis B in mainland China, Hong Kong, Macau and Taiwan.
Lead Product(s): GalNAc-RNAi,Pegylated Interferon alpha 2a
Therapeutic Area: Infections and Infectious Diseases Product Name: AB-729
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Arbutus Biopharma
Deal Size: $300.0 million Upfront Cash: $40.0 million
Deal Type: Partnership December 13, 2021
Details:
Cialis®, and the generic equivalent Tadalafil, is in a class of medications called phosphodiesterase (PDE) inhibitors. Tadalafil is used to treat erectile dysfunction and the symptoms of benign prostatic hyperplasia (BPH; an enlarged prostate).
Lead Product(s): Tadalafil
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: ECI Pharmaceuticals LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 10, 2021
Details:
Under the terms of the agreement, Peptron grants Qilu an exclusive global right and license to develop, manufacture, sell, and commercialize PAb001-ADC for the treatment of cancers.
Lead Product(s): PAb001-ADC
Therapeutic Area: Oncology Product Name: PAb001-ADC
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: Peptron
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 16, 2021
Details:
Cend presented favorable clinical results at the European Society for Molecular Oncology (ESMO) meeting September 2020 and is advancing into Phase 2 clinical trials in pancreatic cancer with CEND-1 in combination with gemcitabine and nab-paclitaxel.
Lead Product(s): CEND-1,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Product Name: CEND-1
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Cend Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 16, 2021
Details:
Under the terms of the agreement, Qilu Pharmaceutical will receive the exclusive rights to market firibastat for the treatment of difficult-to-treat / resistant hypertension in China, including Hong Kong and Macau.
Lead Product(s): Firibastat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: QGC001
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Quantum Genomics
Deal Size: Undisclosed Upfront Cash: $50.0 million
Deal Type: Licensing Agreement October 19, 2020
Details:
Companies have entered into an exclusive licensing agreement for the manufacture, development and commercialization of Vicineum for the treatment of BCG-unresponsive non-muscle invasive bladder cancer and other types of cancer in China, Hong Kong, Macau and Taiwan.
Lead Product(s): Vicineum
Therapeutic Area: Oncology Product Name: VB4-845
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Sesen Bio
Deal Size: $35.0 million Upfront Cash: $12.0 million
Deal Type: Agreement July 31, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
